Snapshot
Danaher Corp /De/ reported $5.94B of revenue in Q2 2025, up 3.4% year over year, with diluted EPS of $0.77 and an operating margin of 12.8%.
- Revenue
- $5.94B
- YoY growth
- +3.4%
- Diluted EPS
- $0.77
- Operating margin
- 12.8%
What management said
- •For more than two decades, we've all benefited from your outstanding financial leadership, your thoughtful guidance, and trusted partnership.
- •Strong growth in our bioprocessing business, paired with disciplined cost management, enabled us to exceed both our adjusted operating profit margin and cash flow expectations for the quarter.
- •Academic and government demand remained soft as expected, with ongoing uncertainty around research funding.
- •We're well-positioned in attractive end markets, driven largely by non-discretionary healthcare needs and supported by strong secular growth drivers.
- •On top of this, our strong balance sheet and free cash flow generation positions us well to further enhance our portfolio going forward.
- •Sales were $5.9 billion in the second quarter, and we delivered 1.5% core revenue growth.
- •Geographically, core revenues in developed markets were up low single-digits, with North America up slightly and a high single-digit increase in Western Europe.
- •Core revenues in high-growth markets were flat overall, as solid performance outside of China was offset by a mid-single-digit decline in China.
- •Growth in our biotechnology and life sciences businesses in China was more than offset by declines in diagnostics due to volume-based procurement and reimbursement changes implemented in late 2024.
- •Our adjusted operating profit margin of 27.3% was flat year-over-year as the favorable impacts of higher volume leverage, product mix, and disciplined cost management were offset by productivity investments to reduce our structural costs.
- •Adjusted diluted net earnings per common share of $1.80 were up approximately 5% year-over-year.
- •We generated $1.1 billion of free cash flow in the quarter and $2.2 billion in the first half of the year, resulting in a year-to-date free cash flow-to-net income conversion ratio of 143%.
What went well
- •Strong execution with the Danaher Business System drove solid second quarter results, with sales of $5.9 billion and 1.5% core revenue growth.
- •Strong growth in the bioprocessing business paired with disciplined cost management let the company exceed both its adjusted operating profit margin and cash flow expectations for the quarter.
- •Bioprocessing consumables led globally with low double-digit growth driven by commercial demand and large pharma and CDMO customers, with bioprocessing fall-through of over 50% in the first half.
- •The company generated $1.1 billion of free cash flow in the quarter and $2.2 billion in the first half, a year-to-date free cash flow-to-net income conversion ratio of 143%.
- •Cepheid exceeded expectations with low double-digit non-respiratory reagent growth, including double-digit or better growth in sexual health, virology, and hospital-acquired infections, with the multiplex vaginitis panel up over 75% in the US.
- •Adjusted diluted EPS of $1.80 was up approximately 5% year-over-year.
What went wrong
- •Bioprocessing equipment revenues remained below historical trends, with order delays as trade policy created incremental noise and slowed customer decision-making on larger capacity projects; 2025 is expected to be a down year for equipment.
- •Core revenues in high-growth markets were flat overall, dragged by a mid-single-digit decline in China from diagnostics volume-based procurement and reimbursement changes, with an expected $150 million adverse impact in 2025.
- •Academic and government demand remained soft amid ongoing uncertainty around research funding.
- •The early-stage discovery biotech market is at low activity levels (though stable), as the wave of venture investment from the pandemic era has waned.
- •Global trade tensions and tariff uncertainty created an overhang, particularly on pharma capacity-expansion decisions.
Guidance changes
| Metric | Period | Previous | Current | Change |
|---|---|---|---|---|
| Adjusted diluted EPS (full year) | FY2025 | ~$7.60 (January) | high end ~$7.80 | Raised ~$0.20 for cost actions and better first-half FX |
| Bioprocessing revenue growth | FY2025 | high single-digit | high single-digit | Maintained |
| Bioprocessing core growth | 2H2025 (Q3 and Q4) | — | high single-digit | Reaffirmed |
| Life sciences segment growth | FY2025 | — | flat full year (2H up low single-digit) | ~$150M step-up 1H to 2H |
| Respiratory revenue | FY2025 | $1.7 billion | $1.7 billion | Maintained (tracking slightly north of $900M in 1H) |
| Structural cost-out savings | FY2025 | $150 million | $150 million | Reaffirmed; about half achieved |
| Tariff cost exposure | FY2025 | ~$350 million | ~couple hundred million | Lowered; company plans to offset all tariffs paid |
Performance breakdown
| Metric | YoY change | Reason |
|---|---|---|
| Core revenue | +1.5% | Solid execution despite a dynamic operating environment; developed markets up low single-digits, high-growth markets flat. |
| Developed markets core revenue | up low single-digits | North America up slightly and Western Europe up high single-digits. |
| High-growth markets core revenue | flat | Solid performance outside China offset by a mid-single-digit decline in China. |
| China core revenue | down mid-single-digit | Biotech and life sciences growth more than offset by diagnostics declines from volume-based procurement and reimbursement changes implemented in late 2024. |
| Bioprocessing consumables | low double-digit growth | Commercial demand and large pharma and CDMO customers; smaller customers stable but below historical levels. |
| Adjusted operating profit margin | flat at 27.3% | Favorable volume leverage, product mix, and disciplined cost management offset by productivity investments to reduce structural costs. |
| Adjusted diluted EPS | +~5% to $1.80 | Higher volume, mix, and cost management. |
| Cepheid non-respiratory reagents | low double-digit growth | Installed base expansion at large IDNs and menu adoption across sexual health, virology, and hospital-acquired infections. |
Earnings call themes & trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing recovery and book-to-bill | seventh consecutive quarter of book-to-bill solidly over one (Q1) | book-to-bill around one with lumpiness in equipment orders; consumables strong | steady |
| Global trade tensions and tariffs | ~$350 million tariff exposure | ~couple hundred million exposure; net neutral in China; pharma capacity decisions delayed | declining (exposure lower) but persistent uncertainty |
| China diagnostics volume-based procurement | $150 million expected 2025 impact | $150 million impact unchanged; volumes consistent with Q1 | steady |
| Bioprocessing equipment demand | below historical trends | still below historical trends; funnels improving but order decisions delayed | steady (down year expected for 2025) |
| China outside diagnostics | — | firming up with slight bioprocessing growth and stimulus aiding life science tools | rising |
| Respiratory endemic rate | $1.7 billion guide held for ~3 years | maintained at $1.7 billion; open to revisiting after another year | steady |
| AI as a tailwind for biotech | — | viewed positively as it shifts spend toward validated, commercialized therapies where Danaher has most volume | rising |
| CFO succession | — | Matt Gugino to succeed Matt McGrew as CFO at end of February 2026 | rising |
Q&A summary
Bank of America (Michael Ryskin): What were bioprocessing order trends and book-to-bill, and did orders accelerate from Q1?
Bioprocessing trends in Q2 were consistent with Q1; consumables led with low double-digit growth driven by large pharma and CDMO customers, while equipment stayed below historical trends with improving funnels but delayed orders. Book-to-bill was around one with equipment lumpiness, and first-half activity fully supports high single-digit core growth in the second half.
Bank of America (Michael Ryskin): Where are global trade tensions showing up, and do you expect recovery?
Trade uncertainty mainly overhangs pharma, where capacity-expansion decisions are hard to make until tariff outcomes are clear; management expects that overhang to clear in the next 6 to 12 months. Applied and clinical markets are less affected, with consistent clinical volumes.
Wolf Research (Doug Schenkel): Are the bioprocessing growth and pricing assumptions in guidance unchanged, and is bioprocessing guidance up while DNM is down?
High single-digit growth for the ~$6 billion bioprocessing piece is maintained. Pricing was about 1.5-2% in the first half and should be similar or slightly better in the second half, with a typical Q3 volume step-down then a Q4 step-up. The full-year segment guide is maintained, slightly better in bioprocessing and a touch worse in discovery and medical.
Jefferies (Tycho Peterson): Why isn't the entire EPS beat flowing through to guidance?
Roughly $0.20 from cost actions and better first-half FX was flowed through (taking the high end to ~$7.80), but another ~$0.15-$0.20 from a strong respiratory start and favorable second-half FX was held back to see how the dynamic environment plays out, while keeping respiratory at $1.7 billion.
Evercore (Vijay Kumar): Was there any tariff-driven pull-forward, and is bioprocessing high single-digit growth sustainable into 2026?
No meaningful pull-forward was seen in surveys or customer conversations. Management views bioprocessing as a durable high single-digit growth market and plans to give preliminary 2026 thoughts on the October earnings call.
Leerink (Puneet Souda): What is the updated tariff cost exposure and gene-therapy/AAV exposure?
Tariff exposure is now roughly a couple hundred million dollars versus the prior $350 million, with China effectively net neutral via internal levers. Gene-therapy exposure is small as Danaher is ~85% focused on proteins; Aldevron/Sarepta revenue is expected to be about $30 million for the full year with minimal second-half contribution.